Clinical Trial: Long-term Clinical and Biological Evaluation of Patients With Severe Forms of Pemphigus Treated by Rituximab

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: EVALUATION CLINIQUE ET BIOLOGIQUE A LONG TERME DES PATIENTS ATTEINTS DE FORMES SEVERES DE PEMPHIGUS TRAITES PAR LE RITUXIMAB

Brief Summary: The purpose of this study is to study the midterm clinical evaluation, biological parameters and immune reconstitution after Rituximab treatment for Pemphigus.

Detailed Summary:
Sponsor: University Hospital, Rouen

Current Primary Outcome: Rate of relapse after 5 years of treatment [ Time Frame: five years ]

Primary outcome measure is the evaluation of Rate of relapse after 5 years of treatment by rituximab for patient with pemphigus. The relapse is defined by the reappearance of mucous or cutaneous érosives lésions proved by histology and by direct immunofluorescence


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: University Hospital, Rouen

Dates:
Date Received: February 17, 2011
Date Started: June 2011
Date Completion:
Last Updated: September 12, 2012
Last Verified: September 2012